Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

Lipids in Health and Disease

Research

Tetsuro Miyazaki¹  Hitoshi Sato¹  Shinya Okazaki¹  Takashi Kiyanagi¹  Katsumi Miyauchi¹  Kazunori Shimada¹  Makoto Hiki¹  Kosei Tanimoto¹  Katsuhiko Sumiyoshi¹  Hiroshi Mokuno¹  Hiroyuki Daida¹  Takeshi Kurata¹  Atsumi Kume¹ 

[1] Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan;

关键词: Fenofibrate;    Coronary Stenting;    Lipoprotein Profile;    Cholesterol Ester Transfer Protein;    Late Lumen Loss;   

DOI  :  10.1186/1476-511X-9-122

 received in 2010-09-14, accepted in 2010-10-25,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe association between modulation of detailed lipoprotein profiles and cholesterol ester transfer (CET) activity by peroxisome proliferator-activated receptor (PPAR)-a agonists in patients with coronary artery disease remains unclear. We assessed lipid profiles, plasma CET activity, and in-stent intimal hyperplasia after fenofibrate treatment in patients who underwent elective coronary stenting.MethodsForty-three consecutive patients who underwent elective coronary stenting were randomized to the fenofibrate group (300 mg/day for 25 weeks, n = 22) or the control group (n = 21). At baseline and follow up, CET activity and lipoprotein profiles were measured, and quantitative coronary angiography was performed.ResultsIn the fenofibrate group, the levels of large very low-density lipoprotein cholesterol, and small low-density lipoprotein (LDL) cholesterol decreased and those of small high-density lipoprotein (HDL) cholesterol increased. Besides, CET activity decreased independent of the effect of fenofibrate on total and LDL cholesterol. The reduction of CET activity significantly correlated with the increase in LDL particle size (r = 0.47, P = 0.03) and the decrease of triglycerides in large HDL subclasses (r = 0.48, P = 0.03). Although there were no significant differences in restenosis parameters between the two groups, low CET activity significantly correlated with the inhibition of neointimal hyperplasia (r = 0.56, P = 0.01).ConclusionsFenofibrate inhibited CET activity and thereby improved atherogenic lipoprotein profiles, and reduced intimal hyperplasia after coronary stenting.

【 授权许可】

CC BY   
© Miyazaki et al; licensee BioMed Central Ltd. 2010